Intellia Therapeutics. Every tracked FinTwit mention of $NTLA, newest first. 23 mentions since the first on Jul 18, 2025. See the price chart.
April 2026 · 4 mentions
Apr 27
Adam Feuerstein ✡️ — $NTLA HAE study results were both expected and unimpressive relative to current treatments. The company will need to raise a lot of money to sell a therapy that is not going to lau…↗
Adam Feuerstein ✡️ — $NTLA Intellia says CRISPR-based treatment for rare disease reduced swelling attacks in pivotal trial
Attack rates dropped 87%, relative to placebo. Just over 60% were entirely a…↗
Adam Feuerstein ✡️ — @MichaelMaiello @YHdjdhd $NTLA offered the 30 calendar guidance, not the FDA.↗
Dec 1
Adam Feuerstein ✡️ — $NTLA update on FDA clinical hold should be imminent, if not overdue already.↗
November 2025 · 2 mentions
Nov 8
Adam Feuerstein ✡️ — CRISPR-based treatment cuts cholesterol and triglycerides in early study https://t.co/Y03kJtJZYN via @matthewherper $CRSP $NTLA $LLY↗
Adam Feuerstein ✡️ — I don’t want $NTLA to go bankrupt. That would require spending all its cash. Wasteful. I said the company should return cash to shareholders. Big difference.
One of the lessons o…↗
Oct 29
Adam Feuerstein ✡️ — $NTLA FDA places ATTR-PN and CM trials on clinical hold.
https://t.co/HE46BvvZUy↗
Oct 28
Adam Feuerstein ✡️ — @robdubparker Save "blame the short seller" for tomorrow's $NTLA posting. You need to pace yourself.↗
Oct 28
Adam Feuerstein ✡️ — We've reached the blame-the-patient stage in the $NTLA retail cult meltdown.
July 2025 · 1 mention
Jul 18
Space Investor — Feeling good today.
Just opened a fresh account with $100K in cash from profit-taking yesterday.
No rush to deploy it, waiting for the obvious deals.
Keeping a close eye on $DMY…↗
Adam Feuerstein ✡️ — $BMRN tonight said it was divesting Roctavian, its underperforming gene therapy for hemophilia A.
$NTLA take note. Time to wind down, return cash to shareholders. Salvage what you…↗
Oct 27
Adam Feuerstein ✡️ — @ZinselmeyerB @MichaelMaiello @_OliverVenture @GeneInvesting I disagree. The Hy's Law/DILI case absolutely impacts everyone because it changes the $NTLA risk/benefit equation. Wil…↗
Oct 27
Adam Feuerstein ✡️ — For Intellia $NTLA , CRISPR drug’s safety concern is an existential threat
It is difficult to imagine a viable future for the biotech following pause in trials.
Hy's Law, drug-i…↗
Adam Feuerstein ✡️ — Intellia $NTLA pauses two late-stage CRISPR gene-editing trials after emergence of safety concern
-45%
https://t.co/Bx2IeFUSE8 via @Jasonmmast↗
Oct 27
Adam Feuerstein ✡️ — $NTLA For a company with a history of disclosure issues, this should be investigated. https://t.co/7JsEKvuPKR↗
Oct 27
Adam Feuerstein ✡️ — $NTLA liver tox forces suspension of ATTR clinical trials
https://t.co/0Lw7FPbNmD↗
Oct 8
Space Investor — $NTLA
1-Bagger secured.
We ride. https://t.co/6rMn3GnYUB↗
Oct 7
Adam Feuerstein ✡️ — @Sanctuary_Bio @A_May_MD @BlaseBio ARK Funds have been buying $NTLA recently, for instance.↗
Oct 3
Space Investor — Hey everyone 👋
It’s been a minute, hope you’re all doing well.
I sometimes miss the action, but tuning out the noise and playing the long game has been deeply rewarding, both in…↗